Cortexyme EVP of R&D Leslie Holsinger resigns effective July 31, 2022

Quince Therapeutics, Inc.

Dr. Holsinger receives $339,000 cash severance (9 months' base salary) in a lump sum.
Health care continuation benefits and 12-month extension of vested equity exercise period provided.
Additional change-in-control severance and accelerated vesting available if a change in control occurs within 3 months post-departure.
Company anticipates entering into a consulting agreement with Dr. Holsinger for transition through year-end.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leslie Holsinger

Executive Vice President of Research and Development

QNCX · Quince Therapeutics, Inc.

Effective: 2022-07-31
Filed: July 22, 2022, 7:59 PM ET

On July 20, 2022, the Company entered into a transition agreement (the “Separation Agreement”) with Leslie Holsinger, Ph.D., relating to her resignation from her role as the Executive Vice President of Research and Development of the Company, effective as of July 31, 2022 (the “Departure Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Leslie Holsinger resigned as Executive Vice President of Research and Development at Quince Therapeutics, Inc..

Action: resigned
Role: Executive Vice President of Research and Development

Exact text from the filing

On July 20, 2022, the Company entered into a transition agreement (the “Separation Agreement”) with Leslie Holsinger, Ph.D., relating to her resignation from her role as the Executive Vice President of Research and Development of the Company, effective as of July 31, 2022 (the “Departure Date”).

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-200068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.